Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01299714 · ClinicalTrials.gov registry record
Community Awareness, Resources and Education (CARE II): Project 3
A clinical trial, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- 191
- Enrollment target
NCT01299714 is a clinical trial that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 191 participants.
The verdict
NCT01299714 has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 191 participants
- Enrollment target
Study Summary
Researchers at The Ohio State University and the University of Michigan are working together to understand cancer of the cervix. One of the areas they are studying is how stress you may experience in your life effects the way you respond to GARDASIL®. GARDASIL® is a vaccine approved by the Food and Drug Administration (FDA) to prevent some types of Human Papillomavirus (HPV) infection which can cause cancer of the cervix. Participants are being recruited from the Appalachian region of Ohio.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2011-02 |
| Est. Completion | 2015-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01299714
The ClinicalTrials.gov registry entry for NCT01299714 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01299714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01299714 about?
NCT01299714 is a clinical study titled "Community Awareness, Resources and Education (CARE II): Project 3". Researchers at The Ohio State University and the University of Michigan are working together to understand cancer of the cervix. One of the areas they are studying is how stress you may experience in your life effects the way you respond to GARDASIL®. GARDASIL® is a vaccine approved by the Food and ...
What is the current status of trial NCT01299714?
This trial is currently completed. The enrollment target is 191 participants. The study started on 2011-02. Estimated completion is 2015-04.
Who is sponsoring clinical trial NCT01299714?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.